Full text is available at the source.
Abstract
Oral semaglutide may reduce HbA1c levels and body weight more effectively than other antidiabetic agents.
- Oral semaglutide shows similar effectiveness to other GLP-1 receptor agonists in managing type 2 diabetes.
- The safety profile of oral semaglutide is comparable to other GLP-1 receptor agonists.
- A randomized controlled trial did not show a reduction in the incidence of the composite primary endpoint.
- A reduction in cardiovascular and all-cause mortality was observed with oral semaglutide.
- This formulation may be beneficial for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk who prefer oral medication over injections.
Simplified